The estimated Net Worth of Tess Burleson is at least $51.3 Mille dollars as of 7 June 2022. Ms. Burleson owns over 27,700 units of Salarius Pharmaceuticals stock worth over $51,280 and over the last 5 years she sold SLRX stock worth over $0. In addition, she makes $0 as Independent Director at Salarius Pharmaceuticals.
Tess has made over 2 trades of the Salarius Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 27,700 units of SLRX stock worth $4,986 on 7 June 2022.
The largest trade she's ever made was buying 27,700 units of Salarius Pharmaceuticals stock on 7 June 2022 worth over $4,986. On average, Tess trades about 3,561 units every 94 days since 2019. As of 7 June 2022 she still owns at least 32,050 units of Salarius Pharmaceuticals stock.
You can see the complete history of Ms. Burleson stock trades at the bottom of the page.
Tess Burleson CPA serves as Independent Director of the Company. Ms. Burleson has served as the chief operating officer of Translational Genomics Research Institute, a nonprofit research institute, since 2007, and has served as the president of TGen Health Ventures, LLC a venture capital company, since 2009. Prior to joining Translational Genomics Research Institute, Ms. Burleson served as the chief financial officer at Lovelace Medical Foundation from 1997 to 2007, president at Lovelace Scientific Resources from 1993 to 1997, and as a senior associate Tax, Audit & Advisory Services at KPMG from 1990 to 1993. Ms. Burleson earned a B.B.A in Accounting from University of New Mexico, the Anderson Graduate School of Management and an M.B.A. from University of New Mexico. Salarius believes that Ms. Burleson is qualified to serve on its board of directors as a result of her extensive operational experience in the biotechnology industry and experience in financial and accounting matters.
Tess Burleson is 53, she's been the Independent Director of Salarius Pharmaceuticals since 2019. There are 7 older and 1 younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.
Tess's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum e Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: